HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume – Here’s Why

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw an uptick in trading volume on Friday . 48,356 shares traded hands during mid-day trading, a decline of 5% from the previous session’s volume of 51,076 shares.The stock last traded at $15.49 and had previously closed at $15.85.

Analyst Ratings Changes

Several analysts have recently issued reports on HCM shares. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a report on Monday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.88.

HUTCHMED Stock Performance

The business has a 50-day simple moving average of $14.21 and a 200 day simple moving average of $15.43. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Trust Inc. grew its position in shares of HUTCHMED by 131.5% during the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after buying an additional 4,378 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in HUTCHMED by 23.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock worth $233,000 after purchasing an additional 2,916 shares during the period. Ameriprise Financial Inc. grew its holdings in HUTCHMED by 4.7% in the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares during the period. Bank of America Corp DE increased its stake in HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after purchasing an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares during the period. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.